US FDA Approves First Artificial Iris

June 1, 2018: By Jon Swedien
The HumanOptics CustomFlex artificial iris is custom designed to match the patient's natural iris color.

The HumanOptics CustomFlex Artificial Iris is custom designed to match the patient’s natural iris color.

The US FDA has approved the first stand-alone prosthetic iris in the US, the agency announced May 30.

The prosthetic iris is a surgically implanted device, which manufacturer HumanOptics of Germany has dubbed the CustomFlex Artificial Iris.

The device is designed to treat adults and children with irises that are missing or damaged due to a congenital condition called aniridia, the FDA said.

The CustomFlex also is indicated to treat iris defects due to other conditions, such as albinism, traumatic injury, or surgical removal due to melanoma.

The device is made of thin, foldable medical-grade silicone and is custom-sized and colored for each patient, the FDA said.

A surgeon implants the device by making a small incision, inserting the device, unfolding it, and smoothing out the edges using surgical instruments. The prosthetic iris is held in place by the anatomical structures of the eye or, if needed, by sutures, the agency said.

More than 70 percent of patients reported significant decreases in light sensitivity and glare, as well as an improvement in their health-related quality of life following the procedure during a non-randomized clinical trial of 389 adult and pediatric patients with aniridia or other iris defects, the FDA said.

The agency also said 94 percent of patients were satisfied with the artificial iris’ appearance. The study found low rates of adverse events associated with the device or the surgical procedure.

The CustomFlex Artificial Iris was approved through a premarket approval application.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023